Business Context and Reporting Period
This Form 8-K filing by Quoin Pharmaceuticals Ltd. (QNRX) is dated April 29, 2025. The report addresses a regulatory matter concerning the company's listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance event rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. The company received written notice from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per American Depositary Share (ADS). The company's ADS closing bid price remained at or above $1.00 from April 9 to April 28, 2025, leading Nasdaq to close the matter.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or new risks. The document serves solely to notify investors that the previous compliance issue regarding the minimum bid price has been resolved.
Investor Verification Checklist
- Verify the current trading price of QNRX ADSs to ensure continued compliance with the $1.00 minimum bid requirement.
- Confirm the status of the company's listing on the Nasdaq Capital Market via official exchange announcements.
- Review prior 8-K filings to understand the timeline of the initial non-compliance notice.